 EMERYVILLE, Calif., Dec. 11, 2020 GLOBE NEWSWIRE -- Adamas Pharmaceuticals, Inc. Nasdaq: ADMS today announced that the compensation committee of the companys board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the companys common stock, at a per share exercise price of 4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the companys common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the companys board of directors in March 2016 under Rule 5653c4 of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. 